Low prevalence of Cfr-mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy

Fecha de publicación

2016-04-13T15:13:41Z

2016-04-13T15:13:41Z

2013

2016-04-13T15:13:46Z

Resumen

Linezolid is an effective antimicrobial agent to treat methicillin-resistant Staphylococcus aureus (MRSA). Resistance to linezolid due to the cfr gene is described worldwide. The present study aimed to analyze the prevalence of the cfr-mediated linezolid resistance among MRSA clinical isolates in our area. A very low prevalence of cfr mediated linezolid resistance was found: only one bacteremic isolate out of 2 215 screened isolates. The only linezolid resistant isolate arose in a patient, previously colonized by MRSA, following linezolid therapy. Despite the low rate of resistance in our area, ongoing surveillance is advisable to avoid the spread of linezolid resistance.

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

Public Library of Science (PLoS)

Documentos relacionados

Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0059215

PLoS One, 2013, vol. 8, num. 3

http://dx.doi.org/10.1371/journal.pone.0059215

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

cc-by (c) Sierra, J.M. et al., 2013

http://creativecommons.org/licenses/by/3.0/es